Current report No. 49/2021 K – Supplement to current report 49/2021 dated November 30, 2021 concerning the change in the composition of the Management Board of Celon Pharma S.A.

Date prepared: November 30, 2020, 05:02 PM

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.

Content of the report:

The Management Board of Celon Pharma S.A. (“Company”) as a supplement to current report No. 49/2021 dated November 30, 2021, hereby forwards a statement of Ms Dorota Zwolińska, appointed on November 30, 2021 by the Company’s Supervisory Board to the Management Board as of December 15, 2021.

According to the submitted statement, Ms Dorota Zwolińska, as of the date of appointment, shall not be engaged in any business activity competitive to the Company, shall not be a partner in any other competitive civil, partnership or capital company, and shall not participate in a competitive legal entity as a member of its body. Ms Dorota Zwolińska is not listed in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register.